7d
Investor's Business Daily on MSNAmgen Shrugs Off A Surprise Setback For One Of Its Obesity DrugsAmgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...
Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...
Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...
The Motley Fool on MSN8d
Amgen Surpasses Q4 Earnings ForecastsFree cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, ...
Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results